The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

PURPOSE: Combinations of endocrine therapy (ET) and targeted therapy (CDK4/6 or mTOR inhibitors) are standard of care for HR+/HER2- metastatic breast cancer (MBC). When ET is not effective, chemotherapy is commonly used. However, clinical outcomes of chemotherapy in the endocrine-resistant setting a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Autores principales: Chainitikun, Sudpreeda, Long, James P, Rodriguez-Bautista, Ruben, Iwase, Toshiaki, Tripathy, Debu, Fujii, Takeo, Ueno, Naoto T.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7501162/
https://ncbi.nlm.nih.gov/pubmed/32720114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05837-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares